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Abstract
Background: Omitting extensive lymph node dissection could reduce esophagectomy morbidity in patients
without lymph node metastases. Sentinel node biopsy may identify abdominal or thoracic lymph node metastases,
thereby differentiating treatment. Feasibility of this approach was investigated in Western European esophageal
cancer patients with advanced disease, without lymph node metastases at diagnostic work-up.
Methods: The sentinel node biopsy was performed in eight esophageal cancer patients with cT1-3N0 disease. One
day pre-operatively, Tc-99m-labeled nanocolloid was endoscopically injected around the tumor.
Lymphoscintigraphy was performed 1 and 3 h after injection. All patients underwent robotic thoracolaparoscopic
esophagectomy with two-field lymph node dissection. Intraoperatively, sentinel nodes were detected by gamma
probe. The resection specimen was analyzed for remaining activity by scintigraphy and gamma probe.
Results: Visualization rates of lymphoscintigraphy 1 and 3 h after tracer injection were 88 and 100 %, respectively.
Intraoperative identification rate was 38 %. Postoperative identification was possible in all patients using the gamma
probe to analyze the resection specimen. In 5/8 patients, lymph node metastases were found at histopathology,
none of which was detected by the sentinel node biopsy. No adverse events related to the sentinel node biopsy
were observed.
Conclusions: In our advanced esophageal cancer patients who underwent thoracolaparoscopic esophagectomy,
the sentinel node biopsy did not predict lymph node status. Probably the real sentinel node could not be
identified due to localization adjacent to the primary tumor or bypassing due to metastatic tumor involvement.
Therefore, we consider the sentinel node biopsy not feasible in advanced esophageal cancer.
Keywords: Esophageal cancer, Sentinel lymph node biopsy, Lymphatic metastasis, Lymphadenectomy, Minimally
invasive surgery
Background
Esophageal cancer is the eighth most common malig-
nancy in the world affecting more than 450,000 people
worldwide, and the incidence is rapidly increasing [1].
For patients with locoregional disease, the best chance
for cure is offered by radical esophagectomy [2]. As the
esophagus has a unique submucosal lymphatic drainage
system, the lymphatic spread of esophageal cancer is
unpredictable and highly variable [3]. For example, the
prevalence of cervical lymph node metastases in patients
with gastroesophageal junction tumors and those with
tumors in the distal third of the esophagus is 17 and
23 %, respectively [4].
Current staging modalities have limited predictive
value for lymphatic involvement in esophageal cancer
patients. Regional lymph node status is mainly defined
by computed tomography (CT) and 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET), or combined
FDG-PET/CT [5]. However, suboptimal imaging quality
often leads to incorrect assessment of locoregional tumor
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extent [5]. Therefore, during transthoracic esophagectomy
(TTE), an extensive mediastinal and upper abdominal
lymph node dissection (LND) is always performed to clear
all possible metastatic disease. As the cervical region is a
common site of tumor recurrence, some surgeons routinely
perform a cervical LND as well [4, 6, 7].
The transthoracic extensive mediastinal lymph node
dissection is accompanied by substantial cardiopulmonary
morbidity [2]. Surgical strategies such as a transhiatal
approach and minimally invasive techniques have been
employed to reduce the morbidity [8, 9]. For patients
without lymph node metastases in the resected specimen
(pN0), the extensive LND of TTE may be regarded redun-
dant. In these patients, morbidity could be reduced by tai-
loring the extent of LND. This could be accomplished by
the application of sentinel node navigation surgery.
A sentinel node (SN) is defined as the lymph node that
receives lymphatic flow directly from the primary tumor,
being the first site of metastatic spread [10]. Depending
on the tracer used, SNs can be detected by a gamma
camera, a gamma probe, CT lymphography, magnetic
resonance imaging (MRI) lymphography, or by observing
blue dye. The SN concept states that when pathologic
analysis of the detected SN(s) shows no tumor invasion,
extensive dissection of the lymph nodes that drain the
SN(s) can be omitted [11]. SN biopsy is now widely
adopted in the management of early stage breast cancer
and melanoma [11–13].
In esophageal cancer, SN mapping by radioactive
tracer was first described by Kitagawa et al. in 2000 [14].
In subsequent years, several other clinical studies on this
subject have been performed, predominantly in Japanese
institutes [15–19].
The aim of the current study was to assess the feasi-
bility and safety of SN mapping in Western European




A total of eight patients with resectable esophageal can-
cer who were scheduled to undergo esophagectomy with
two-field LND were included in our feasibility study.
Routine diagnostic work-up consisted of esophagogas-
troduodenoscopy (EGD) with biopsy, radial endoscopic
ultrasonography (EUS) (GIF-UM130, Olympus, Ham-
burg, Germany), CT scan of the chest and abdomen,
ultrasonography (US) of the neck with fine needle aspir-
ation (FNA) when indicated, and lung function testing
and bronchoscopy in case of suspected airway ingrowth.
Patients were eligible for SN biopsy if all of the following
criteria were fulfilled: (i) proven adenocarcinoma (AC)
or squamous cell carcinoma (SCC) of the esophagus; (ii)
resectable disease (i.e., cT1-3 or cT4pleura/crus); (iii) no
pre-operative evidence of lymph node metastases (cN0,
cM0); and (iv) no neoadjuvant therapy.
Radiocolloid injection and pre-operative SN identification
One day before surgery patients underwent EGD under
light sedation. Using a 9.8-mm gastroscope (GIF-140,
Olympus, Hamburg, Germany), 400 MBq Tc-99m-la-
beled nanocolloid (Amersham Cygne, Eindhoven, The
Netherlands) in a maximum volume of 2 mL was injected
into the submucosal layer overlaying the tumor in four
quadrants (two proximal and two distal from the tumor;
Fig. 1).
One hour and approximately 3 h after injection, static
images in the anterior, posterior, and lateral planes were
obtained by a dual-head gamma camera with a low-energy,
high-resolution (LEHR) collimator (Argus®; Philips Medical
Systems, Best, The Netherlands) to locate focal areas of
radioactivity (Figs. 2 and 3).
Surgical procedure and intraoperative SN identification
All patients underwent thoracolaparoscopic esophagec-
tomy with two-field LND aided by the Da Vinci™ robotic
system (Intuitive Surgical, Sunnyvale, USA) [20]. Dissected
lymph nodes included the paratracheal, subcarinal, aorto-
pulmonary window, peri-esophageal, celiac, and lesser
omental nodes. The digestive tract was reconstructed by a
gastric conduit, which was anastomosed in the neck.
During surgery, potential SNs in the thoracic and ab-
dominal cavities were identified by a laparoscopic hand-
held gamma probe (Europrobe II; Eurorad, Strasbourg,
France). Radioactivity of the cervical region was assessed
with the handheld gamma probe through the cervical in-
cision at the left side and percutaneously at the right
side of the neck. After the resected specimen was removed
Fig. 1 Peritumoral injection of the radioactive tracer into four
quadrants during esophagogastroscopy
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from the patient, the thoracic and abdominal cavities were
explored with the gamma probe for remaining the
radioactivity.
Postoperative SN identification
At the Department of Pathology, the resected specimen
was opened and was attached on a paraffin board. In this
way, overlap in radioactivity from the tumor and from
possible lymph nodes was avoided. Lymphoscintigraphy
of the resected specimen was performed at the Depart-
ment of Nuclear Medicine in order to visualize the loca-
tion of the focal radioactivity; possible SNs were marked.
Subsequently, the radioactivity of the detected possible
SNs was counted with the handheld gamma probe, and
the identified hot nodes were separated from the resected
specimen for individual histopathologic examination.
Histopathologic examination
The resected esophageal specimen including the remaining
non-sentinel lymph nodes were fixed in 4 % formalin for
24 h. Non-sentinel lymph nodes were identified by slicing
the fatty tissue surrounding the esophagus and gastric car-
dia. The resected specimen and non-SNs, cut in largest
diameter, were fixed in formalin and embedded in paraffin.
Tissue sections (3 μm) were stained with hematoxylin and
eosin (H&E) for routine histopathologic examination. All
resected specimens were examined by one experienced on-
cologic pathologist (MS).
SNs were processed according to a standard protocol.
After formalin fixation and paraffin embedding, step sec-
tions of 3-μm thick were cut at five levels with 250-μm
intervals for H&E staining. When no lymph node me-
tastases could be identified by H&E examination, im-
munohistochemical analysis was performed at each
level with CAM 5.2 (Becton-Dickinson Biosciences, San
Jose, USA, catalog# 349205) in case of primary adenocar-
cinoma or CK AE1/3 (Neomarkers/Lab Vision, Fremont,
USA, catalog# MS-343-P) in case of SCC to detect micro-
metastases or isolated tumor cells.
Results
The median age at the time of surgery was 62 (range,
45–71) years (Table 1). The tumor was located in the
middle third part of the esophagus in two (25 %) patients,
the lower third in five (63 %) and the gastroesophageal
junction in one (13 %). The median tumor size was 3.5
(range, 2–8) cm. Histopathologic examination of the
resected specimens revealed that 50 % of the tumors
were adenocarcinomas and 50 % were squamous cell
carcinomas.
Pre-operative lymphoscintigraphy
No complications of the SN procedure were noticed.
The lymphoscintigraphy performed 1 h after radiocolloid
injection identified possible SNs in seven out of eight pa-
tients, resulting in a visualization rate of 88 %. A median
Fig. 2 Example of scintigraphic examination (thoracic part) performed 1 h (left) and 3 h (right) after radioactive tracer injection. A focal area of
radioactivity is noticed in the left cervical region
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Fig. 3 Scintigraphic examination (abdominal part) performed 1 h (left) and 3 h (right) after radioactive tracer injection in the same patient as in
Fig. 2. A focal area of radioactivity is seen beneath one of the injection sites. ANT anterior; POST posterior; ABD abdominal
Table 1 Overview of the 8 esophageal cancer patients having undergone SN biopsy








# ln metastases # SN
tumor pos
Histol. pTNM
1 69 F cT1smN0M0 1 5 0 – 4 29 0 0 SCC T1N0M0
2 57 M cT3N0M0 2 2 0 1 1 29 10 0 AC T3N1M1a
3 69 M cT3N0M0 4 4 0 5 3 39 4 0 AC T3N0M1a
4 63 M cT1mN0M0 3 3 2 5 1 35 2 0 SCC T1N1M0
5 45 M cT3N0M0 2 2 1 2 3 23 4 0 AC T3N1M1a
6 60 M cT3N0M0 2 4 2 5 3 33 5 0 SCC T3N1M1a
7 71 M cT2N0M0 0 3 0 4 1 30 0 0 AC T1N0M0
8 54 M cT1N0M0 4 7 0 5 5 14 0 0 SCC T1N0M0
Median 62 – – 2 3.5 0 5 3 30 3 0 – –
Legend
AC adenocarcinoma, cTNM clinical tumor node metastasis stage, F female, Histol histology, Hr(s) hour(s), intra-op number of intra-operatively identified structures
with focal radioactivity by gamma probe, Ln lymph node, M male, Pos positive, pTNM pathologic tumor node metastasis stage, SCC squamous cell carcinoma, Scint
scintigraphy, Scint 1 hr number of focal areas of radioactivity as identified by scintigraphic examination performed 1 h after injection, Scint 3 hrs number of focal
areas of radioactivity as identified by scintigraphic examination performed 3 h after injection, Scint specimen number of focal areas of radioactivity as identified by
scintigraphic examination of the resected specimen, # hot SN ex vivo number of hot sentinel nodes identified by gamma probe examination of the resected specimen,
SN sentinel node
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of two SNs (range 0–4) were detected by the lymphos-
cintigraphy performed 1 h after injection (Table 1). The
visualization rate of lymphoscintigraphy performed 3 h
post injection was 100 %, with a median of 3.5 (range 2–7)
identified SNs.
Intraoperative SN detection
With the intraoperative gamma probe, the identification
rate was 38 % (three patients out of eight). The main
cause of failure was the accumulation of the radioactive
tracer in the lymph nodes in direct proximity to the
tumor, with the tumor radioactivity surpassing the radio-
activity of surrounding lymph nodes. In the three pa-
tients, a total of five SNs could be detected with the
intraoperative gamma probe. These five SNs were de-
tected cervically (n = 3), para-esophageally (n = 1), and
subcarinally (n = 1).
SN detection in resected specimen
Scintigraphic examination of the resected specimen re-
vealed a median of five SNs (range 1–5) in all patients.
The identification rate was 100 %. When analyzing the
resected specimen with the gamma probe, in all eight
patients, one or more SN(s) were detected. Therefore,
the post-surgical identification rate for the gamma probe
was 100 %. A median number of three SNs (range 1–5)
were detected by gamma probe analysis of the resected
specimens.
In all five patients with lymph node metastases in the
resected specimen, the SN was tumor negative even
after immunohistochemical analysis and additional serial
sectioning.
Discussion
In our Western European study group of patients with
esophageal cancer who underwent minimally invasive
thoracolaparoscopic surgery, the SN procedure did not
predict lymph node status. Most probably, the sentinel
node could not be identified due to close proximity to
the tumor, which surpassed the radioactivity of sur-
rounding lymph nodes. In Western European countries,
esophageal cancer patients present with advanced dis-
ease in the absence of screening programs. Although at
clinical work-up, patients seem to be without lymph
node metastases, histopathologic examination of the
resection specimen reveals lymph node metastases in
the majority of patients [21]. Therefore, although our
feasibility study contains only a low number of patients,
we conclude that the SN procedure is not feasible in
patients with advanced esophageal cancer. The complex
and vast lymphatic drainage system of the esophagus
contributes to the unreliability of the SN procedure.
Another contributing factor could be a learning
curve of performing the SN procedure during
thoracolaparoscopic esophagectomy. Of note, four out
of five patients with lymph node metastases had T3 dis-
ease. Ovrebo et al. reported lymph node metastases in
74 % of patients with pT3 tumors [22], which raises the
question whether depth of tumor invasion is a better
predictor of lymph node involvement than the SN
procedure.
Some technical issues deserve more consideration. In
our series, lymphoscintigraphy 1 and 3 h after radioactive
tracer injection resulted in visualization rates of 88 and
100 %, respectively. The higher rate in the latter is prob-
ably due to further flow of tracer particles in the lym-
phatics, resulting in the appearance of more first echelon
lymph nodes. These results exceed those reported in the
literature (60–92 %; Table 2), despite the fact that the time
between tracer injection and initial lymphoscintigraphy in
those studies was longer (range 3–12 h) [17, 23]. This
could be explained by the variation in particle size of the
radioactive tracers used. As shown in Table 2, the most
commonly used tracer in Japan is Tc-99m-labeled
stannous colloid [14, 15, 17–19, 23, 24] (particle size
400–500 nm), whereas in the Western world, it is Tc-
99m nanocolloid [25–27] (<80 nm). The larger the
particle size, the longer it takes to pass through the
lymphatic system. However, our SN identification rate
is comparable to the pooled SN identification rate
with Tc-99m of 0.970, reported in a recently published
meta-analysis [28].
In order to determine the location of the SNs, most re-
search groups produce lymphoscintigraphic images in 1
or 2 planes: the anterior [14, 24, 29–31], posterior, or
both [16, 17]. However, due to overprojection of injec-
tion sites, it may be difficult to image SNs. In order to
increase the yield, we added an oblique plane to the an-
terior and posterior acquisition planes. Additionally, in
the first patient, we performed a single photon emission
CT (SPECT) study. Despite these efforts, visualization of
peritumoral SNs remained difficult due to massive reten-
tion of radioactivity at the injection sites. This may have
caused false-negative examinations. Overall, the false
negative rate of our study (100 %) is identical to that of
Kosugi et al. [17], but substantially higher than results
reported in four other series (4–22 %) [15, 16, 23, 27].
The false negative results could also be caused by
metastatic tumor cells. When either the lymphatic drain-
age channels or the lymph nodes are blocked by tumor
cells, the tracer may not be able to enter the initial
lymphatic drainage of the tumor and may follow an al-
ternative route, in that way bypassing the SNs. This
hypothesis is supported by data from the literature. In
43 patients with esophageal or gastric cancer having
undergone SN mapping with 0.75 mCi 99mTc-Sn colloid,
radioisotope uptake was significantly decreased in lymph
nodes in which more than 60 % of the lymph node
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contained metastatic tumor cells [15]. Remarkably,
when reviewing the current literature on SN biopsy in
esophageal cancer, 4 (36 %) of 11 studies included patients
with clinical suspicion of lymph node metastases [15, 16,
18, 27]. As this is an indication for extensive LND, SN bi-
opsy in these patients offers no added value. For this rea-
son, our aim was to include only cN0 patients in our
feasibility study. Nonetheless, histopathologic examination
of the resected specimens revealed lymph node metastases
in five (63 %) of eight patients.
Our intraoperative gamma probe detection rate was
38 %. Eight other research groups have attempted to in-
traoperatively identify SNs with a gamma probe as well
(Table 2) [14–16, 19, 23–25, 27]. Lamb et al. reported an
intraoperative detection rate of 100 % [27]. An explan-
ation for their excellent results could be the timing of
the injected radioactive tracer immediately prior to sur-
gery, which allowed for the identification of early lymph-
atic spread. Yet, the authors reported no screening for
the undetected lymph nodes of the resected specimens
(e.g., with a gamma camera). In our opinion, the intraop-
erative gamma probe is beneficial only in detecting hot
nodes in the cervical region and for exploring the ab-
dominal and thoracic cavities for remaining radioactivity
after resection. Ex vivo SN identification by means of
the gamma probe was possible in all (100 %) patients,
which is comparable to the 90–95 % reported in the lit-
erature (Table 2) [15, 17]. As lymphoscintigraphy visual-
izes radioactive tracer accumulation as well as tracer
pathways, the actual amount of SNs identified by gamma
probe analysis of the resected specimens in our series
was less than the number of areas with high amounts of
radioactivity as identified by lymphoscintigraphic exam-
ination of the resected specimens.
As an alternative for the radionuclide procedure, Suga
et al. have developed interstitial CT lymphography to de-
tect SNs [32, 33]. With this technique, the water-soluble
iodine contrast medium iopamidol is endoscopically
injected into the submucosal layer surrounding the
tumor. By multiplanar reconstruction and maximum
intensity projection images reconstructed from the trans-
axial post-contrast CT images, the route of enhanced
lymphatic vessels can be visualized. The first lymph nodes
with direct connection to these lymphatic vessels are con-
sidered the SNs. In 12 patients with superficial esophageal
cancer, a median of 2.3 SNs were detected. All pre-
operatively detected SNs were identified during surgery.
With a sensitivity of 100 % and with no false negative
cases, this technique seems promising [32, 33]. In a recent
meta-analysis, a pooled detection rate of 0.970, an ac-
curacy of 0.902, and an overall estimated sensitivity of
0.831 were reported for this technique; however, patients
Table 2 Overview of the literature on SN mapping with a radioactive tracer in esophageal cancer (including the results of the
current feasibility study)





Arima [15] 19 SCC 99mTc Sn No n.a. Intra + ex
vivo
n.a. 95 % 78 % 22 % 78 %
Bohanes [25] 1 SCC 99mTc nano Yes Directly after
injection
Intra n.a. n.a. n.a. n.a. n.a.
Burian [26] 20 AC 99mTc colloid
+ dye
? n.a. ? 85 % ? ? ? ?
Fujii [23]a 61 ? 99mTc Sn Yes ? Intra 92 % ? 92 % 14 % ?
Kato [16] 25 SCC 99mTc ReS Yes +/− 12 h after
injection
Intra 92 % ? 91.3 % 8.7 % 86.7 %
Kitagawa 2000
[14]a
16 ? 99mTc Sn Yes ? Intra 88 % ? 93 % ? 89 %
Kitagawa 2001
[24]a
33 ? 99mTc Sn ? ? Intra ? ? ? ? 85 %
Kosugi [17] 10 ? 99mTc Sn Yes 3 h after injection Ex vivo 60 % 90 % 77.8 % 100 % 0 %
Lamb [27] 57 AC 99mTc nano No n.a. Intra + ex
vivo
n.a. 100 % 96 % 4 % ?
Tanaka [18] 1 SCC 99mTc Sn Yes 3 h after injection No n.a. n.a. n.a. n.a. n.a.
Yasuda [19] 23 ? 99mTc Sn No n.a. Intra ? ? ? ? ?
Current study 8 AC +
SCC






38 % 38 % 100 % 0 %
Legend
AC adenocarcinoma, ReS rhenium sulfide, Colloid colloid (unspecified), SCC squamous cell carcinoma, DR detection rate, Scint scintigraphy, FN false negative,
Sn tin, Intra intraoperatively, Tc technetium, n.a. not applicable, ? not reported, nano nanocolloid
aThese three reports are from the same research group and describe the results of the same, but enlarged, study population
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with advanced disease were not included [28]. Comparable
favorable results of CT lymphography have been obtained
in other malignancies, such as lung and breast carcinoma
[34–36].
SN mapping could also be done by means of ferumoxide-
enhanced MRI lymphography [37–39]. Similar to the two
techniques described before, superparamagnetic iron oxide
is injected into the submucosa of the peritumoral region
during gastroscopy. Overall sensitivity of this procedure
was only 66 % (four out of six patients), due to absence of
flux of ferumoxides to metastatic lymph nodes in two pa-
tients [38]. An additional disadvantage of this technique in
esophageal cancer is that cardiac motion artifacts limit the
scanning area to the region from the larynx to the carina
and from the gastric cardia to the renal hilus [40]. Conse-
quently, peri-esophageal (i.e., regional) lymph nodes, which
frequently are the first site of metastatic tumor spread, can-
not be assessed. This may cause false negative examinations
as well.
Although dye-guided detection of SNs is commonly
used in breast cancer and melanoma, it has not gained
wide popularity in esophageal cancer. As the lymphatic
drainage of the esophagus is unpredictable and variable,
real-time observation of the lymphatic pathway of esopha-
geal tumors by blue dye is only feasible when the esophagus
is entirely mobilized. This, however, will lead to destruction
of the active lymphatic flow from the primary tumor and
will compromise the further detection of SNs. Furthermore,
it is difficult to differentiate blue colored upper mediastinal
lymph nodes from nodes that are pigmented by anthraco-
sis. Additionally, it is impossible to directly follow the
lymphatic flow from the primary tumor to cervical lymph
nodes. Burian et al. described the application of blue dye in
combination with a radioactive tracer in SN mapping for
esophageal cancer [26]. Blue dye was easily detected in ab-
dominal lymph nodes during laparotomy of patients with
AEG III (subcardial) tumors. In case of distal esophageal or
AEG II carcinomas, SNs located in the lower mediastinum
could only be detected with the radioactive tracer [26]. In a
recent meta-analysis, two studies were included using blue
dye as a tracer, resulting in a pooled detection rate of 0.971,
an accuracy of 0.790, and a sensitivity of 0.811 [28].
Conclusions
In the current feasibility study, the SN procedure did
not predict lymph node status in Western European
esophageal cancer patients who underwent minimally inva-
sive thoracolaparoscopic esophagectomy. The localization
of the SN just adjacent to the tumor as well as the com-
plexity of the esophageal lymph node basin are important
factors in the unreliability of the SN procedure in esopha-
geal cancer patients, and this technique should therefore be
considered not feasible in these patients. However, our
results should be confirmed in larger studies.
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AC: adenocarcinoma; CT: computed tomography;
EGD: esophagogastroduodenoscopy; FNA: fine needle aspiration;
H&E: hematoxylin and eosin; LEHR: low energy, high resolution; LND: lymph
node dissection; MRI: magnetic resonance imaging; SCC: squamous cell
carcinoma; SN: sentinel node; SPECT: single photon emission CT;
TTE: transthoracic esophagectomy.
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